Research Paper Volume 14, Issue 14 pp 5855—5877

Figure 5. Astragalus and AS-IV enhanced PI3K/AKT pathway in vivo and vitro. (A and B) Expression level of Phospho-PI3K, PI3K, Phospho-AKT and AKT in kidney sections collected at 24 hours after CLP surgery following treatment with (250 mg/kg) Astragalus membranaceus or low (5 mg/kg) or high dosage (10 mg/kg) AS-IV. (C and D) Representative images showing Phospho-AKT immunohistochemical staining of mice kidney tissues. (E) Expression level of Phospho-PI3K, PI3K, Phospho-AKT and AKT in HK-2 cells incubated with LPS (1 μg/ml) plus AS-IV at the concentrations of 5, 10, 20 μM for 6 hours. (F) Protein expression of Phospho-PI3K, PI3K, Phospho-AKT and AKT in HK-2 cells incubated with LPS (1 μg/ml) plus AS-IV (20 μM) or PI3K inhibitor IC-87114 (5 μM) for 6 hours. (G) MTT results for AS-IV (20 μM) or PI3K inhibitor IC-87114 (5 μM) treatment on HK-2 cells incubated with LPS (1 μg/ml) for 6 hours. Data are presented as the mean ± SEM (n = 3 per group, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001).